In a latest study on acquired TTP, anti-microthrombotic agent caplacizumab, which is anti-von Willebrand factor (VWF) nanobody [143], has shown significant clinical benefit. The gene discussed is VWF; the disease is thrombotic thrombocytopenic purpura.